PDF(Pubmed)
Abstract：
BACKGROUND: Affective disorders impose a significant burden on public health due to their high prevalence and associated suffering. This study addresses gaps in current literature and clinical practice by providing insights into medication usage trends, which can inform treatment strategies and optimize patient care. The study aims to investigate drug utilization patterns, particularly focusing on defined daily dose/1000/day, among individuals attending a psychiatric outpatient department of a tertiary care hospital.
METHODS: This cross-sectional, prospective drug utilization study included 600 affective disorder patients aged 18 years and above. The study period spanned 12 months, from March 2021 to February 2022. Data on demographics, diagnosis, treatment, and counseling were collected and analyzed using descriptive statistics.
RESULTS: Among the 600 patients analyzed, bipolar mood disorder was the most prevalent (239 patients, 39.83%), followed by depressive disorder (208 patients, 34.67%). Triple therapy was the most common prescription regimen, accounting for 308 encounters (51.33%). The average number of drugs per encounter was 3.75 ± 1.01. A combination of psychotherapy and medication counseling sessions was provided to 594 patients or their relatives, representing 99% of the total encounters.
CONCLUSIONS: The study highlights the prevalent use of triple therapy in managing affective disorders, especially bipolar mood disorder and mania disorder. Effective utilization of essential drug lists and comprehensive patient counseling underscores the importance of holistic care in psychiatric outpatient settings.
CONCLUSIONS: Given the high prevalence of triple therapy, further research into the efficacy and safety of this treatment approach is warranted. Additionally, continued emphasis on patient education and counseling can enhance treatment adherence and overall outcomes in individuals with affective disorders.
METHODS: This cross-sectional, prospective drug utilization study included 600 affective disorder patients aged 18 years and above. The study period spanned 12 months, from March 2021 to February 2022. Data on demographics, diagnosis, treatment, and counseling were collected and analyzed using descriptive statistics.
RESULTS: Among the 600 patients analyzed, bipolar mood disorder was the most prevalent (239 patients, 39.83%), followed by depressive disorder (208 patients, 34.67%). Triple therapy was the most common prescription regimen, accounting for 308 encounters (51.33%). The average number of drugs per encounter was 3.75 ± 1.01. A combination of psychotherapy and medication counseling sessions was provided to 594 patients or their relatives, representing 99% of the total encounters.
CONCLUSIONS: The study highlights the prevalent use of triple therapy in managing affective disorders, especially bipolar mood disorder and mania disorder. Effective utilization of essential drug lists and comprehensive patient counseling underscores the importance of holistic care in psychiatric outpatient settings.
CONCLUSIONS: Given the high prevalence of triple therapy, further research into the efficacy and safety of this treatment approach is warranted. Additionally, continued emphasis on patient education and counseling can enhance treatment adherence and overall outcomes in individuals with affective disorders.
摘要：
背景：由于情感障碍的高患病率和相关痛苦，情感障碍对公共卫生造成了重大负担。本研究通过提供对药物使用趋势的见解，解决了当前文献和临床实践中的差距。这可以告知治疗策略和优化患者护理。该研究旨在调查药物利用模式，特别关注定义的每日剂量/1000/天，在三级护理医院精神科门诊就诊的个人中。
方法：这个横截面，前瞻性药物利用研究包括600名18岁及以上的情感障碍患者。研究期为12个月，从2021年3月到2022年2月。人口统计数据，诊断,治疗,和咨询进行收集和分析，采用描述性统计。
结果：在分析的600名患者中，双相情感障碍是最普遍的(239名患者，39.83%），其次是抑郁症(208名患者，34.67%）。三联疗法是最常见的处方方案，占308次遭遇（51.33%）。每次遇到的平均药物数量为3.75±1.01。为594名患者或其亲属提供了心理治疗和药物咨询相结合的课程，占总遭遇的99%。
结论：该研究强调了三联疗法在控制情感障碍方面的普遍应用，尤其是双相情感障碍和躁狂症。有效利用基本药物清单和全面的患者咨询强调了精神科门诊环境中整体护理的重要性。
结论：鉴于三联疗法的高患病率，有必要进一步研究这种治疗方法的有效性和安全性.此外,继续强调患者教育和咨询可以提高情感障碍患者的治疗依从性和总体结局.
方法：这个横截面，前瞻性药物利用研究包括600名18岁及以上的情感障碍患者。研究期为12个月，从2021年3月到2022年2月。人口统计数据，诊断,治疗,和咨询进行收集和分析，采用描述性统计。
结果：在分析的600名患者中，双相情感障碍是最普遍的(239名患者，39.83%），其次是抑郁症(208名患者，34.67%）。三联疗法是最常见的处方方案，占308次遭遇（51.33%）。每次遇到的平均药物数量为3.75±1.01。为594名患者或其亲属提供了心理治疗和药物咨询相结合的课程，占总遭遇的99%。
结论：该研究强调了三联疗法在控制情感障碍方面的普遍应用，尤其是双相情感障碍和躁狂症。有效利用基本药物清单和全面的患者咨询强调了精神科门诊环境中整体护理的重要性。
结论：鉴于三联疗法的高患病率，有必要进一步研究这种治疗方法的有效性和安全性.此外,继续强调患者教育和咨询可以提高情感障碍患者的治疗依从性和总体结局.
